Therapy with voriconazol for a case of chronic mucocutaneous candidiasis [1];Tratamiento con voriconazol de un caso de candidiasis mucocutánea crónica

Actas Dermo-Sifiliograficas

Volumn 97, Issue 10, 2006, Pages 679-680

  Penate Y ^a   Hernandez J ^a   Hernandez Machin B ^a   Islas, D ^a   Martin A M ^a   Borrego, L ^a  

^a HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; CICLOPIROX; COTRIMOXAZOLE; CYCLODEXTRIN; CYTOCHROME P450; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; RAVUCONAZOLE; VORICONAZOLE;

BLURRED VISION; CHRONIC DISEASE; DRUG BIOAVAILABILITY; DRUG METABOLISM; HUMAN; LETTER; LIVER TOXICITY; MUCOCUTANEOUS CANDIDIASIS; PHOTOPHOBIA; VISUAL IMPAIRMENT;

EID: 33846295472     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(06)73495-0     Document Type: Letter

References (5)

1. Pfaller MA, Messer SA, Houston A, Mills K, Bolmstrom A, Jones RN. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. J Clin Microbiol. 2000;38;3715-7.
2. Tosti A, Piraccini BM, Vincenzi C, Cameli N. Itraconazole in the treatment of two young brothers with chronic mucocutaneous candidiasis. Pediatr Dermatol. 1997;14:146-8.
3. Kamai Y, Maebashi K, Kudoh M, Makimura K, Naka W, Uchida K, et al. Characterization of mechanism of fluconazole resistance in a Candida albicans isolate from a Japanese patient with chronic mucocutaneous candidiasis. Microbiol Immunol. 2004;48:937-43.
4. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis. 2003;37 Suppl 3:S157-87.
5. Guimerá-Martín-Neda F, García-Bustínduy M, Noda-Cabrera A, Sánchez-González R, Montelongo RG. Cutaneous infection by Fusarium: successful treatment with oral voriconazole. Br J Dermatol. 2004;150:777-8.